Obesity management has rapidly evolved—from invasive procedures to highly targeted medical therapies. Traditionally, bariatric surgery offered the most effective results (25–35% weight loss), followed by less invasive options like the gastric balloon (10–15%).

The real breakthrough came with GLP-1–based injectables such as Semaglutide and Tirzepatide, delivering up to 15–22% weight loss through appetite suppression and metabolic effects.

Now, the field is entering a new phase with the launch of Orforglipron (Foundayo)—a once-daily oral GLP-1 therapy.

🔬 What’s new?
First non-peptide oral GLP-1 agonist
No injections or fasting requirements
Around 10–12% weight loss in clinical trials

⚖️ Clinical significance
Although slightly less effective than injectable therapies, orforglipron offers a major advantage: ease of use. This could improve patient acceptance and long-term adherence, making it a strong candidate for early or first-line pharmacotherapy in obesity management.

🇮🇳 India perspective
With rising obesity prevalence and increasing adoption of GLP-1 therapies, oral options like Foundayo may significantly expand access once launched.

🧠 Bottom line

1. The treatment paradigm is shifting:
Surgery → Devices → Injections → Oral therapy

2. The arrival of oral GLP-1 marks a key step toward simpler, scalable, and patient-friendly weight management.